Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)
===================================================================================================================================================================================================

* Natasha B Leighl
* Mary W Redman
* Naiyer Rizvi
* Fred R Hirsch
* Philip C Mack
* Lawrence H Schwartz
* James L Wade
* William J Irvin
* Sreekanth C Reddy
* Jeffrey Crawford
* Jeffrey D Bradley
* Thomas E Stinchcombe
* Suresh S Ramalingam
* Jieling Miao
* Katherine Minichiello
* Roy S Herbst
* Vassiliki A Papadimitrakopoulou
* Karen Kelly
* David R Gandara